Alector LLC

131 Oyster Point Blvd Ste 600, South San Francisco, California, United States$514.8M

Also known as:

alector inc.

Clinical Trials

19 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

67.7%

Phase 2

17.6%

Phase 3

11.8%

Trial Status Distribution

Active, not recruiting

52.9%

Completed

23.5%

Not yet recruiting

2.9%

Recruiting

8.8%

Terminated

11.8%

Clinical Trials

Trials sponsored by this organization (34)

Continuation Study for Latozinemab

Phase 3

Terminated

interventional

Dec 202317 participants

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Phase 1

Recruiting

interventional

Oct 2023347 participants

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Phase 2

Terminated

interventional

Jan 2023197 participants

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Phase 2

Terminated

interventional

Sep 20215 participants

A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD.

Phase 1

Active, not recruiting

Jun 2021180 participants

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Phase 2

Completed

interventional

Jan 2021356 participants

An Open-Label Study to Evaluate Safety of long-term AL001 dosing in FTD

Phase 1

Active, not recruiting

Jan 202132 participants

A Clinical Trial to evaluate AL002 in Participants with early Alzheimer's Disease

Phase 1

Active, not recruiting

Nov 2020265 participants

Page 1 of 5

Approvals

No approval data available

News

No news articles found

Back to Organizations